Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Cibotercept by Keros Therapeutics for Pulmonary Arterial Hypertension: Likelihood of Approval
Cibotercept is under clinical development by Keros Therapeutics and currently in Phase II for Pulmonary Arterial Hypertension. According to GlobalData,...
Data Insights
Risk adjusted net present value: What is the current valuation of Keros Therapeutics's Cibotercept?
Cibotercept is a fusion protein commercialized by Keros Therapeutics, with a leading Phase II program in Pulmonary Arterial Hypertension. According...